克拉屈滨治疗难治复发急性髓系白血病效果与安全性分析

目的：探讨克拉屈滨治疗难治复发急性髓系白血病（AML）的效果与安全性。方法回顾性分析应用含克拉屈滨方案治疗的8例难治复发AML患者临床资料。克拉屈滨剂量为每天5 mg／m2，连用5 d。分析患者疗效及不良反应。结果8例难治复发AML患者中，5例达完全缓解，1例部分缓解，2例无效。不良反应可耐受。结论含克拉屈滨方案治疗难治复发AML效果较好，且不良反应可耐受，值得临床进一步研究。

Efficacy and safety of cladribine in treatment of patients with refractory/relapsed acute myeloid leukemia

Objective To investigate the efficacy and safety of cladribine in the treatment of patients with refractory/relapsed acute myeloid leukemia (AML). Methods The data of 8 patients with refractory/relapsed AML treated with regimens containing cladribine at a dose of 5 mg/m2 per day for 5 consecutive days were retrospectively analyzed. The efficacy and adverse reactions were observed during treatment. Results Among the 8 patients, 5 patients achieved complete remission (CR), 1 patient achieved partial response (PR), and 2 patients obtained non remission (NR). The adverse reactions could be tolerated. Conclusion Regimen containing cladribine is an effective treatment procedure for the patients with refractory/relapsed AML, and its adverse reactions can be tolerated, which requires further clinical study.